An advocacy group criticizes Hims & Hers Health for allegedly misleading Super Bowl ad promoting weight loss products, violating FDA regulations. Read more here.

G/O Media is once again attempting to use AI to churn out content — while simultaneously warning that anything the AI ...

The weight-loss drug is on track to log over $13 billion in global sales in 2025, according to Evaluate, a pharmaceutical intelligence firm. Ozempic, Novo Nordisk’s semaglutide-based diabetes ...

The list extends into the pharma industry, including Pfizer, GSK, and Novo Nordisk. On 14 November, Eli Lilly became a part of this group, after an account using its name and logo sent out a Tweet ...

Verdiva secures pharma veteran as its CMO Dr Mohamed Eid joined Verdiva ... Previously, Dr Eid held senior clinical, medical, and regulatory roles at Novo Nordisk. “We are excited by the potential of ...

driven by the success of Novo Nordisk’s Wegovy (semaglutide), and Eli Lilly’s Zepbound (tirzepatide). Wegovy is forecast to bring in $19.6bn in sales in 2030, with Zepbound estimated to make $27.6bn ...

When it comes to football, there isn’t much Kendall Simmons hasn’t seen. Throughout his 45 years, MTSU’s second year ...

New York, New York-- (Newsfile Corp. - February 7, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Novo Nordisk (NYSE: NVO) and certain ...

Kepler Capital analyst David Evans maintained a Hold rating on Novo Nordisk (0QIU – Research Report) on February 5 and set a price target of ...

The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower ...

Danish pharmaceutical behemoth Novo Nordisk on Wednesday reported better-than-expected net profit in the fourth quarter, amid ...